Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: Is there an association?

Current Opinion in Cardiology

Volumn 25, Issue 4, 2010, Pages 406-410

  Athyros, Vasilios G ^a   Tziomalos, Konstantinos ^b   Karagiannis, Asterios ^a   Wierzbicki, Anthony S ^c   Mikhailidis, Dimitri P ^d  

^a Second Propedeutic Department of Internal Medicine   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

coronary heart disease; haemorrhagic stroke; ischaemic stroke; primary prevention; secondary prevention; statins

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MEGADOSE; FATALITY; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION;

ANTICHOLESTEREMIC AGENTS; BRAIN ISCHEMIA; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTRACRANIAL HEMORRHAGES; PRIMARY PREVENTION; PYRROLES; RISK FACTORS; SECONDARY PREVENTION; STROKE;

EID: 77953812374     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283393c1a     Document Type: Review

References (38)

1. Tell GS, Crouse JR, Furberg CD. Relation between blood lipids, lipoproteins, and cerebrovascular atherosclerosis. A review. Stroke 1988; 19:423-430.
2. Oliver MF. Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. BMJ 2000; 320:459-460.
3. Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986; 2:933-936.
4. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality. 30 years of follow-up from the Framingham study. JAMA 1987; 257:2176-2180.
5. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
6. Tirschwell DL, Smith NL, Heckbert SR, et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 2004; 63:1868-1875.
7. Iso H, Jacobs DR, Wentworth D, Neaton JD. Cohen JD for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989; 320:904-910.
8. Noda H, Iso H, Irie F, et al. Low-density lipoprotein cholesterol concentrations and death due to intraparenchymal hemorrhage: the Ibaraki Prefectural Health Study. Circulation 2009; 119:2136-2145.
9. Zhao D, Liu J, Wang W, et al. Epidemiological transition of stroke in China twenty-one-year observational study from the Sino-MONICA-Beijing Project. Stroke 2008; 39:1668-1674.
10. Vartiainen E, Dianjun D, Marks JS, et al. Mortality, cardiovascular risk factors, and diet in China, Finland, and the United States. Public Health Rep 1991; 106:41-46.
11. Sai XY, He Y, Men K, et al. All-cause mortality and risk factors in a cohort of retired military male veterans, Xi'an, China: an 18-year follow up study. BMC Public Health 2007; 7:290-297.
12. Ueshima H, Sekikawa A, Miura K, et al. Cardiovascular disease and risk factors in Asia. Circulation 2008; 118:2702-2709.
13. Gotto AM Jr, Farmer JA. Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002; 106:1595-1598.
14. Suh II, Jee SH, Kim HC, et al. Low serum cholesterol and hemorrhagic stroke in men. Korean Medical Insurance Corporation Study. Lancet 2001; 357:922-925.
15. Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 1989; 20:1460-1465.
16. Yusuf S, Reddy KS, Ounpuu S, Anand S. Global burden of cardiovascular diseases. Part I: General consideration, the epidemiology transition, risk factors and impact of urbanization. Circulation 2001; 104:2746-2753.
17. De Caterina R, Scarano M, Marfisi R, et al. Cholesterol-lowering interventions and stroke. Insights from a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2010; 55:198-211.
18. Mascitelli L, Pezzetta F, Goldstein MR. Low cholesterol, statin therapy, and intracerebral haemorrhage. Hong Kong Med J 2009; 15:403.
19. Meier N, Nedeltchev K, Brekenfeld C, et al. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Stroke 2009; 40:1729-1737.
20. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 2003; 9:2425-2443.
21. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009; 203:325-330.
22. Waters DD, Schwartz GG, Olsson AG, et al., MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive CholesterolLowering(MIRACL) substudy. Circulation2002;106:1690-1695.
23. Schwartz GG, Olsson AG, Ezekowitz MD, et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study-a randomized controlled trial. JAMA 2001; 285:1711-1718.
24. Kinlay S, Schwartz GG, Olsson AG, et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003; 108:1560-1566.
25. Murphy SA, Cannon CP, Wiviott SD, et al. Reduction in Recurrent Cardiovascular Events With Intensive Lipid-Lowering Statin Therapy Compared With Moderate Lipid-Lowering Statin Therapy After Acute Coronary Syndromes: From the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Trial. J Am Coll Cardiol 2009; 54:2358-2362.
26. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDLcholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006; 17:626-630.
27. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the postacute coronary syndrome lipid-lowering trials A to Z and PROVE ITTIMI 22. Circulation 2006; 113:1406-1414.
28. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H, Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol 2007; 100:747-752.
29. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002; 360:7-22.
30. Collins R, Armitage J, Parish S, et al., Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004; 363:757-767.
31. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
32. Goldstein LB, Amarenco P, Szarek M, et al., SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study. Neurology 2008; 70:2364-2370.
33. Goldstein LB, Amarenco P, Zivin J, et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2009; 40:3526-3531.
34. Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation 2010; 121:143-150.
35. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem 2009; 9:1291-1297.
36. Amarenco P, Goldstein LB, Callahan A 3rd, on behalf of the SPARCL Investigators. Baseline blood pressure, low-and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis 2009; 204:515-520.
37. Amarenco P, Benavente O, Goldstein LB, et al. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 2009; 40:1405-1409.
38. Amarenco P, Goldstein LB, Sillesen H, et al. Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 2010; 41:426-430.